Erratum: Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

Double Blind ◽

Double Blind Placebo ◽

Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study

Yearbook of Medicine ◽

10.1016/s0084-3873(09)79349-6 ◽

2009 ◽

Vol 2009 ◽

pp. 15-17

Author(s):

D.L. Kimpel

Keyword(s):

Rheumatoid Arthritis ◽

Double Blind ◽

Double Blind Placebo ◽

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

Arthritis & Rheumatism ◽

10.1002/art.21778 ◽

2006 ◽

Vol 54 (5) ◽

pp. 1390-1400 ◽

Cited By ~ 682

Author(s):

Paul Emery ◽

Roy Fleischmann ◽

Anna Filipowicz-Sosnowska ◽

Joy Schechtman ◽

Leszek Szczepanski ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Efficacy And Safety ◽

Treatment Results ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging ◽

Methotrexate Treatment

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

Arthritis & Rheumatism ◽

10.1002/art.23383 ◽

2008 ◽

Vol 58 (4) ◽

pp. 964-975 ◽

Cited By ~ 194

Author(s):

Jonathan Kay ◽

Eric L. Matteson ◽

Bhaskar Dasgupta ◽

Peter Nash ◽

Patrick Durez ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Double Blind ◽

Double Blind Placebo ◽

THU0100 Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.2065 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 188.1-188 ◽

Cited By ~ 4

Author(s):

B. Hsu ◽

S. Sheng ◽

J.S. Smolen ◽

M.E. Weinblatt

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Methotrexate Therapy ◽

Phase 2 ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

Arthritis & Rheumatology ◽

10.1002/art.38949 ◽

2015 ◽

Vol 67 (2) ◽

pp. 334-343 ◽

Cited By ~ 67

Author(s):

Roy M. Fleischmann ◽

Nemanja S. Damjanov ◽

Alan J. Kivitz ◽

Anna Legedza ◽

Thomas Hoock ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1164186.624873 ◽

2009 ◽

Author(s):

Ladislav Senolt

Keyword(s):

Rheumatoid Arthritis ◽

Jak Inhibitor ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Faculty Opinions recommendation of Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727328077.793564275 ◽

2019 ◽

Author(s):

Ladislav Senolt

Keyword(s):

Rheumatoid Arthritis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group

SAT0145 Efficacy and Safety of Sirukumab in Patients with Active Rheumatoid Arthritis despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of A Randomized, Double-Blind, Placebo-Controlled Study: Table 1.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.3741 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 717.1-717

Author(s):

T. Takeuchi ◽

C. Thorne ◽

G. Karpouzas ◽

S. Sheng ◽

W. Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Drug Treatment ◽

Controlled Study ◽

Efficacy And Safety ◽

Treatment Results ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Inflammation Research ◽

10.1007/s00011-019-01218-y ◽

2019 ◽

Vol 68 (4) ◽

pp. 261-274 ◽

Cited By ~ 1

Author(s):

David L. Boyle ◽

Samuel E. DePrimo ◽

Cesar Calderon ◽

Dion Chen ◽

Paul J. Dunford ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Mechanism Of Action ◽

Phase 2 ◽

Histamine H4 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

H4 Receptor ◽

Orally Active

The efficacy and safety of the herbal medicine geonchildan for patients with active rheumatoid arthritis: study protocol for a randomized, double-blind, placebo-controlled, parallel pilot trial

Trials ◽

10.1186/s13063-018-2849-3 ◽

2018 ◽

Vol 19 (1) ◽

Cited By ~ 2

Author(s):

Seunghoon Lee ◽

Yeeun Cho ◽

Jihye Kim ◽

Jung Won Kang ◽

Ga Young Yoon ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Herbal Medicine ◽

Study Protocol ◽

Pilot Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo